Tuesday, April 03, 2012 12:12:47 PM
By Matt Nesto | Breakout – 1 hour 50 minutes ago
If a 30% year-to-date rally in the Biotech industry (BTK) has caught your eye but crimped your courage, it may be time to think again. That's because for all its short-term strength, the sexy corner of the otherwise stodgy Health Care sector (XLV) has really just regained lost ground, when in fact, a new cycle of innovation is just getting underway.
"I think we are beginning to see signs of life amongst biotechs, with new products coming to market that are gaining traction," says Marshall Gordon, health care analyst at Clear Bridge Advisors, a New York based asset manager with $55 billion in assets under management. "Innovation is a great way to get paid, in any market environment or regulatory environment."
Of course, the upside of biotech's innovation is paired with the downside of its legendary volatility, which is an inescapable side-effect for this business, as is the omnipresent opportunity (or threat) of being acquired, since Gordon agrees that every small biotech company is a potential target.
"If you look at the pharmaceutical industry today, they are desperate for products, and the way to get those is by buying biotech," he says.
To that extent, Gordon has flagged three small players that he thinks possess tremendous upside.
(other stock info deleted)
Gordon also owns Human Genome Sciences (HGSI) --an $8 stock that was $30 about a year ago, but like Onyx, is being undervalued. He thinks its new Lupus drug, the first such treatment t0 gain FDA approval in the past 50 years, is bigger than most analysts expect and will deliver better than expected sales once doctors start using and seeing the results firsthand.
_________________________________________________
http://finance.yahoo.com/blogs/breakout/big-pharma-desperate-product-small-biotech-answer-141833680.html
HGSI
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM